NMC Section 6 — Doctor Marketing Rules 2026 Complete Update | ICG

Author: Rohit Gupta · Co-Founder, ICG · IIT BHU Pharmaceutical Engineering + IIM Rohtak · July 2026

The National Medical Commission Code of Professional Ethics 2026 revision is the most consequential update to doctor marketing regulation in India in a decade. The revision explicitly includes digital content within Section 6's scope for the first time, formalises the educational content carve-out, and adds an influencer-marketing provision that affects thousands of doctors who have commercial arrangements with supplement, wellness, and health tech brands.

ICG has applied the NMC compliance framework to 150+ healthcare client engagements since 2018. Zero formal NMC, DCI, or CDSCO complaints across the portfolio. This guide is the operational compliance framework we use — not a legal interpretation document.

What is NMC Section 6?

Section 6 of the NMC Code of Professional Ethics governs advertising and promotion by registered medical practitioners. It is the primary regulatory framework that determines what Indian doctors can and cannot say in any marketing communication — website copy, Instagram posts, Google Ads, YouTube videos, WhatsApp Broadcasts, and email newsletters.

Pre-2026, the Code was largely interpreted from provisions drafted for print advertising. The 2026 revision updates the language for the digital environment.

The 5 changes in the 2026 revision

Change 1: Digital content explicitly included

The 2026 revision makes explicit what was previously implicit: all digital content produced by or on behalf of a registered medical practitioner — including social media posts, video content on digital platforms, website copy, and electronic messaging directed at the general public — is subject to Section 6.

Practical impact: A doctor who previously treated their personal Instagram account as outside NMC's reach now has clear regulatory clarity that it is within scope. A clinic's WhatsApp Broadcast to patients is advertising under Section 6 if it primarily serves to promote the practice.

Change 2: Educational content carve-out formalised

The 2026 revision creates an explicit carve-out for educational content. Content that primarily serves patient health literacy, scientific education, or public health awareness — without primarily promoting a specific medical practice or soliciting patients — is outside Section 6's advertising prohibition.

This carve-out is the foundation of all doctor YouTube programmes, Instagram Reels, and healthcare blog content that ICG produces. A Reel explaining how hyaluronic acid fillers work is educational. A Reel saying "book with me for fillers in Bandra" is promotional.

The test ICG applies: "Could this content be useful to a patient regardless of which clinic they choose?" If yes — educational. If it only serves patients already considering your specific clinic — promotional.

Change 3: Influencer-marketing provision introduced

Any content produced by a registered medical practitioner for a third-party platform — a supplement brand's Instagram, a health startup's app, a cosmetic company's YouTube channel — for commercial consideration is deemed advertising under Section 6. It must comply with all Section 6 prohibitions.

Practical impact: Doctors who receive payment to promote nutraceuticals, health devices, or wellness products on social media must ensure those promotions comply with NMC Section 6 in addition to ASCI influencer disclosure guidelines. ICG reviews all influencer-type engagements for doctor clients and advises on compliant framing.

Change 4: Identifiability standard clarified for before-and-after

The Section 6 prohibition on before-and-after imagery of identifiable patients now has a clear identifiability standard: a patient is identifiable if their face is visible, if unique physical characteristics enable recognition, or if contextual details (location, unusual presentation, described procedure combination) make identification likely even without a name.

This clarification closes the loophole some clinics used of blurring faces while leaving other identifying features intact. ICG's before-and-after compliance protocol applies the 2026 standard — if there is any reasonable possibility of patient identification, the image is not used without the explicit DPDP-compliant consent process.

Change 5: Patient testimonial consent framework strengthened

Every patient testimonial used in advertising requires documented informed consent specifying: the specific content being used, the platforms on which it will appear, the duration of use, and the patient's right of withdrawal. This consent must be separate from the clinical consent form and specific to the marketing use.

This intersects with DPDP Act 2023 — which requires specific, informed consent for processing of health-adjacent data (the patient's identity + their health-related experience).

What is permitted under Section 6 (with 2026 update)

Prism Pulse content calendar showing the month ahead with Reel, Feed and Story slots colour-coded per day for a healthcare Instagram account" width="1200" height="675" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

What is prohibited under Section 6 (with 2026 update)

The 12-point pre-publication checklist

ICG's content team applies this before publishing any doctor or clinic marketing content:

1. ☐ Primary intent: educates or solicits? If soliciting, is it factual and non-manipulative?
2. ☐ Outcome guarantee language scan ("guaranteed", "100%", "cure", "eliminate permanently")
3. ☐ Before-and-after imagery — is the patient identifiable under the 2026 standard?
4. ☐ Schedule J check — does the content name a specific drug for a listed condition?
5. ☐ Superlative claims — is "best", "leading", "top", "#1" specifically substantiated?
6. ☐ Patient data — is DPDP Act 2023 consent documented for any patient identity used?
7. ☐ Specialisation boundary — is content within the doctor's registered specialisation?
8. ☐ Safety messaging — does content discourage appropriate conventional medical care?
9. ☐ Paid endorsement disclosure — is any commercial arrangement disclosed?
10. ☐ ART Act check (IVF only) — no success rate claims, no donor identification?
11. ☐ DCI check (dental only) — MDS specialisation disclosed, no undue-anxiety language?
12. ☐ Compliance footnote attached to all published articles?

The enforcement landscape in 2026

NMC Section 6 enforcement is complaint-driven. The most common triggers in ICG's analysis of 2025-2026 enforcement patterns:

Before-and-after imagery complaints: Cosmetic specialties. Filed by patients who feel misled by the outcome gap between marketing imagery and their actual result. Also filed strategically by competitors in contested metro markets.

IVF success rate advertising: ART Registry-registered clinics continuing to publish specific success rates in Google Ads or website copy face increasing complaint exposure as ART Act 2021 enforcement matures.

Unsubstantiated superlatives: "Best dermatologist in [city]" on websites without specific evidence continues to generate competitor-filed complaints in competitive urban markets.

Penalty progression: Formal warning → public censure on register → suspension of registration for serious or repeated violations. ICG's compliance programme eliminates exposure to the most commonly targeted violation types.

FAQ

Q1: Does Section 6 apply to a doctor's personal Instagram even if it doesn't mention their clinic? Yes, if the content is produced by the registered medical practitioner and is related to their medical practice in any way. A plastic surgeon's personal Instagram that discusses their approach to rhinoplasty — even without naming their clinic — is within Section 6's scope under the 2026 revision. Pure personal content with no healthcare or professional dimension is outside scope.

Q2: Can a doctor be paid to appear in a pharmaceutical company's medical education programme? Yes — legitimate medical education programmes (CME, advisory boards, speaker programmes) are permitted under UCPMP 2024 subject to appropriate fee disclosure and documentation. These are distinct from promotional advertising. The UCPMP 2024 compliance framework (managed by ICG's pharma practice) governs pharma HCP interactions. For pharma enquiries: WhatsApp ICG on 918130226224.

Q3: What is the difference between the NMC Code and the MCI Code that doctors may be more familiar with? The MCI (Medical Council of India) was replaced by the NMC (National Medical Commission) under the NMC Act 2019. The NMC Code of Professional Ethics supersedes the MCI's Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations 2002. The NMC Code is more comprehensive and — as of the 2026 revision — more specifically applicable to digital marketing.

Q4: If my hospital's marketing department produces non-compliant content featuring me, am I liable? You are not the primary responsible party for content produced by your employer without your involvement. However, if content makes claims in your name or uses your image, you should request that your hospital's marketing team remove the non-compliant element and document your request. Continued use of non-compliant content bearing your name after you've requested removal creates potential shared liability.

Q5: How does ICG ensure compliance across 150+ clients simultaneously? ICG's pre-publication compliance review is a systematic workflow embedded in content production — not a separate final check. Every content brief includes compliance flags. Every draft passes the 12-point checklist. Every piece carries a compliance footnote. The consistency comes from workflow design, not from reviewing each piece in isolation. Zero formal NMC complaints across the portfolio since 2018.

Compliance note: This article reflects ICG's operational compliance interpretation. It is not legal advice. Consult a healthcare lawyer for specific legal guidance on NMC compliance.